Company: BGLC
Filing Date: 2025-06-23
Form Type: 8-K
Source: 0001477932-25-004754
Chunk: 0

Company: BioNexus Gene Lab Corp
Filing Date: 2025-06-23
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Chief Financial Officer

On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “ Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately.

Ms. Chong, age 62, has over 25 years of senior financial leadership experience, including serving as the Chief Financial Officer of Avillion Berhad from 2013 until November 2024. She is a member of the Association of Chartered Certified Accountants (ACCA) and the Malaysian Institute of Accountants (MIA), and brings deep expertise in corporate financial reporting, internal controls, and regional operations oversight.

Ms. Chong will concurrently serve as Chief Financial Officer of the Company’s wholly-owned subsidiary, MRNA Scientific Sdn. Bhd., and will perform the responsibilities of the Principal Financial Officer of BioNexus Gene Lab Corp. in accordance with U. S. federal securities laws and Nasdaq rules.

Under the terms of her employment agreement with MRNA Scientific Sdn. Bhd., Ms. Chong will receive a monthly salary of RM15,000 (approximately USD $3,500), plus benefits including medical coverage, fuel allowance, and eligibility for discretionary bonus compensation. Her appointment was reviewed and recommended by the Company’s Nomination and Corporate Governance Committee and Compensation Committee, and approved by the Board of Directors. The Company has also entered into an indemnification agreement with Ms. Chong governed by the laws of the State of Wyoming.

There are no family relationships between Ms. Chong and any director or executive officer of the Company, and she has not been involved in any related party transaction requiring disclosure under Item 404(a) of Regulation S-K.

Concurrent with the new appointment, Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.

A copy of the Service Contract between the Company and Ms. Chong is attached hereto as Exhibit 10.7.

Item 9.01Financial Statements and Exhibits